ImmPort Quarterly Newsletter

Quarterly Newsletter

Welcome to our first quarterly newsletter! The ImmPort team is always working to bring you new data and features. We are excited to share these highlights below to help you get the most out of your ImmPort experience.

What's New? COVID-19 Studies New Datasets Deep Learning

New COVID-19 Data Has Arrived!

Our latest data release shares high-quality immunological findings for COVID-19 and other immunology studies. Check out all new datasets, or select individual COVID-19 studies below.

SDY1655: Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19, PI: Akiko Iwasaki - Yale School of Medicine (Nature, Aug 2020)

SDY1648: Sex Differences in Immune Responses to SARS-CoV-2 that Underlie Disease Outcomes, PI: Akiko Iwasaki - Yale School of Medicine (Nature, Aug 2020)

SDY1641: Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension, PI: Guoliang Zhang - National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital (Emerging microbes & infections, Dec 2020)

SDY1640: Targets of T Cell Responses to SARS-Cov-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, PI: Alessandro Sette - La Jolla Institute for Immunology (Cell, May 2020)

SDY1662: An Inflammatory Cytokine Signature Predicts Covid-19 Severity and Survival, PI: Sacha Gnjatic - Icahn School of Medicine at Mount Sinai (Nature Medicine, Oct 2020)

Click on a study number for more information and links to PubMed and the Journal

Deep Learning with ImmPort Data

We are always thrilled to see how the research community utilizes ImmPort data for innovative research and discovery. Dr. Zicheng Hu, research scientist at the University of California, San Francisco’s Bakar Computational Health Sciences Institute, utilized ImmPort data to develop a convolutional neural network for predicting clinical outcomes from cytometry data. His work was recently published in PNAS AND his model is available on ImmPort for your use.

Big Data in Immunology:
ImmPort at FOCiS 2020

The ImmPort team and collaborators hosted a series of talks and a hands-on workshop during the 2020 Federation of Clinical Immunology Societies (FOCIS ) Annual Meeting.

Share Your Data with ImmPort

Your data goes further when shared and can lead to innovative discoveries. Join your research colleagues in sharing data through the ImmPort platform. ImmPort team members are always happy to assist with data uploads. Contact us at ImmPort_Helpdesk@immport.org

ImmPort contains: 435+ studies and 60K subjects for 111 diseases supported by 1800 experiments, 5.9M test results, and 1M laboratory results
See a Data Visualization of All Studies

ImmPort is a recommended data repository by PLoS One and Nature's Scientific Data, and holds the Core Trust Seal of Approval for Core Trustworthy Data Repositories